Lixte Biotechnology Holdings, Inc. · NASDAQ:LIXT
Lixte Biotechnology — Nomad Power Systems — Investor Presentation (July 2026)
58 slides from Lixte Biotechnology's investor presentation, July 2026
Slide 1: Nomad Power Systems Inc.
Nomad Power Systems Inc. (Nasdaq : NMAD ) © 2026 NOMAD Transportable Power Systems, Inc. - Confidential
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matter
Slide 3: Mobile Energy Infrastructure
NOMAD TRANSPORTABLE POWER SYSTEMS Mobile Energy Infrastructure For a Capacity-Constrained Grid Confidential | 2026
Slide 4: Legal Disclaimer
Legal Disclaimer Important Information for Investors statements are based on expectations and assumptions of the Company, including: (i) anticipated financial performance; (ii) estimates of capital and operating This presentation (together with any accompanying oral or written communications, this “
Slide 5: The Traditional Grid Was Built For Predictable Demand
The Traditional Grid Was Built For Predictable Demand. AI, electrification, and resiliency are changing that. Deployable infrastructure is emerging as a necessary layer between fixed grid constraints and dynamic power demand. © 2026 NOMAD Transportable Power Systems, Inc. - Confidential
Slide 6: The Grid Cannot Keep Up with AI
The Grid Cannot Keep Up with AI 2.3 TW Generation & storage awaiting grid interconnection 5–7 Yrs Median time to commercial operation, vs. ~2 years historically 100+ GW AI & data center power demand projected by 2035 — buildout cannot wait for grid queues Source: LBNL Interconnection Queue Report; G
Slide 7: Mobile Utility-Scale Infrastructure
Mobile Utility- Scale Infrastructure Deployed in under 1 hour No permitting. No civil works. Utility-grade interconnection UL 9540 validated. Live grid integration. Utilities, C&I, OEMs, and government Relocatable across territories and sectors. © 2026 NOMAD Transportable Power Systems, Inc. - Confi
Slide 8: Why Deployable Infrastructure Wins
Why Deployable Infrastructure Wins Four structural advantages that fixed infrastructure cannot replicate SPEED FLEXIBILITY Under 1 hour. No permits, no civil works, Relocatable. Seasonal deployment. Parallel no interconnection queue. scalability across service territories. ECONOMICS RESILIENCY Peak
Slide 9: NOMAD: A Distinct Category
NOMAD: A Distinct Category Mobility + utility-grade validation + grid integration — no competitor combines all three Stationary BESS Diesel Rental Emerging Mobile BESS NOMAD Mobility Fixed ✔ Yes ✔ Yes ✔ Yes Permitting Required Extensive Minimal Minimal Minimal Utility-Grade Interconnection ✔ Yes ✗ N
Slide 10: Modular Infrastructure Platform
Modular Infrastructure Platform Three Voyager platforms — one mission, deployable anywhere 999 kW | 2.0 MWh | LFP 500 kW | 2.0 MWh | LFP 500 kW | 1.0 MWh | LFP Voyager Eagle Voyager Falcon Voyager Hawk High Power. Compact Footprint. Extended Duration. Versatile Power. Agile Power. Rapid Response. •
Slide 11: Utility-Grade by Design
Utility-Grade by Design UL 9540 Validated Thermal runaway fire propagation standard. Direct utility interconnection. LFP Chemistry Superior thermal stability. 6,000+ cycle life. Lower insurance risk. Integrated Safety Systems Fire detection, suppression, and arc flash mitigation standard. © 2026 NOM
Slide 12: Utility Validation: DSO Electric Cooperative
Utility Validation: DSO Electric Cooperative Peak shaving deployment — pilot converted to purchase DEPLOYMENT OUTCOMES $150k–$300k Seasonal peak shaving savings 1 Season Positive ROI achieved <1 Day Deployment time — no permitting required VALIDATED OUTCOME Pilot converted to outright purchase. Posi
Slide 13: Utility Reliability: Green Mountain Power
Utility Reliability: Green Mountain Power Mission-critical deployment — utility-grade reliability validated in the field DEPLOYMENT OUTCOMES ✔ Prevented a 6-hour outage ✔ Utility-grade integration on live grid ✔ Demonstrated mission-critical reliability “NOMAD’s system provided critical backup capac
Slide 14: Commercial Momentum
Commercial Momentum Utility adoption scaling rapidly — from pilots to multi-unit repeat orders 10x 75% 30+ Average Order Size Growth Inbound Sales Calls Active Utility Sales Cycles From 1-unit pilots to 10+ unit orders Up from 25% — product is pulling demand Up from fewer than 10 — pipeline accelera
Slide 15: Competitive Moat
Competitive Moat Structural barriers that take years to replicate — and compound with every deployment CERTIFICATION UTILITY TRUST UL 9540 validated across the full product line — the safety standard Referenceable Tier-1 deployments create a self-reinforcing trust required for direct utility interco
Slide 16: OEM Channel Partners
OEM Channel Partners Extending NOMAD’s reach through established distribution and defense channels Rental Markets Sentinel Advanced Military Solutions Global leader in temporary power and energy rental Deployable defense infrastructure for contested environments • Present in 100+ countries — utiliti
Slide 17: Diverse End-Market Demand
Diverse End-Market Demand Deployable across utilities, industrial, commercial & government sectors Utility & Grid Services AI & Data Center Power Peak shaving, demand management, outage backup, Bridging interconnection delays for hyperscale and transmission congestion relief edge buildout Oil, Gas &
Slide 18: Deployment Economics & Operating Model
Deployment Economics & Operating Model Three deployment pathways, each generating recurring service revenue Equipment Leasing / Recurring Sales EaaS Services Direct purchase by utilities and Third-party capital funds asset NOC monitoring and fleet C&I customers ownership. management embedded across
Slide 19: Network Operations Center
Network Operations Center 24/7 monitoring — Waterbury, VT Real-Time Fleet Performance Optimization AI-Powered Analytics & Remote Diagnostics Safety Assurance & Compliance Oversight Market Integration & Revenue Optimization © 2026 NOMAD Transportable Power Systems, Inc. - Confidential
Slide 20: Production-Ready Manufacturing
Production-Ready Manufacturing ISO-certified. Multi-site. Scalable on demand. MANUFACTURING PARTNERS Multi-Site Redundancy Three ISO 9001/14001 certified facilities across North America. Modular Assembly 70–90% shared component architecture. Repeatable, scalable production. Demand-Aligned Capacity I
Slide 21: Deployable Energy Infrastructure
NOMAD TRANSPORTABLE POWER SYSTEMS Deployable Energy Infrastructure Mobile energy infrastructure is emerging as a critical layer within a constrained and increasingly dynamic electrical grid. Structural Demand Validated Platform Strategic Position Grid congestion • AI growth • Utility deployments • U
Slide 22: Transforming cancer treatment with Protein Phosphatase 2A
OR ee ae ea ee Ne aaa Cae Ser ips es “Sere es Test C LIXTE g Transforming cancer i" treatment with Protein Phosphatase 2A ee Unveiling the first of a novel class of therapeutic agents
Slide 23: Immunotherapy: Great potential, many challenges
Immunotherapy: Great potential, many challenges Limited Efficacy Safety Risks Intrinsic and acquired Toxicity limits treatment resistance to therapy dosage and duration, limits its impact. affecting efficacy.
Slide 24: Our unique approach: enhance existing therapies with PP2A inhibitors
Our unique approach: enhance existing therapies with PP2A inhibitors Pre-Clinical Evidence: LB-100 is a first-in-class enhancer of immunotherapy IMMUNOTHERAPY Enhanced immunotherapy CHEMOTHERAPY Enhanced chemotherapy efficacy efficacy a a 6 a i AdVUaHLONAWWI e@ Enhances T cell proliferation e Increa
Slide 25: LB-100 is the first PP2A-inhibitor with a promising safety profile
LB-100 LB-100 is the first PP2A-inhibitor with a promising safety profile LB-100 is a small molecule inhibitor of the PP2A phosphatase, a critical enzyme involved in multiple cellular functions. + Demonstrated safety in 2 phase 1 clinical trials NCT01837667 and NCT03027388 * Documented anti-cancer a
Slide 26: LB-100 stimulates cell cycle and inhibits DNA repair
LB-100 stimulates cell cycle and inhibits DNA repair This renders cancer cells more susceptible to chemotherapy agents, thus enhancing the treatment's effectiveness. Cell Cycle * DNA Repair OLIXTE
Slide 27: LB-100: Mechanism of action in combination with immunotherapy
LB-100: Mechanism of action in combination with immunotherapy LB-100 promotes the production of neoantigens and cytokines and enhances T cell proliferation. This reinforces the systemic immune response to cancer, thus enhancing the effectiveness of immunotherapy. LB-100...——C Neoantigen creation Cyt
Slide 28: PP2A inactivating mutations correlate with increased survival
PP2A inactivating mutations correlate with increased survival in unselected cancers after immunotherapy Overall Survival - Immunotherapy Overall Survival - Other therapy (Samstein et al, Nature Genetics 2019, n=1,661) (Zehir et al, Nature Medicine 2017, n=7,564) 1.00 1,00 207 Not Reached 2B 07 4 g 8
Slide 29: 2024 and 2025 milestone publications
2024 and 2025 milestone publications nature RESEARCH ARTICLE Article PPP2RIA mutations portend improved survival after cancer immunotherapy neps fterg/10°035/41606 026 00205.8 Vibe Dal Anno Krsof” Mtsutake Yenc, aoe cheeuaiom Sangheon ee Arnalyn We Mano| Chat peste nenee am eng Uw, Zhe Yuar® Chen Wa
Slide 30: Building a pipeline in multiple cancer indications
Building a pipeline in multiple cancer indications Pre-Clinical Phase 1b Phase 2 Phase 3 Status LB-100 + Immunotherapy Ovarian Clear Cell Cancer Actively Recruiting at MD Anderson And Northwestem. GSK sponsored, completed enrollment 1b dose escalation. LB-100 + Immunotherapy Metastatic MSI Low Colon
Slide 31: LB-100 + Immunotherapy: Ovarian Clear Cell Cancer
LB-100 + Immunotherapy Ovarian Clear Cell Cancer NCT06065462
Slide 32: Loss-of-function mutation in PPP2A shows median survival
Loss-of-function mutation in PPP2A shows 67 months Median Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors vs 9 months for wild type Dai et al Nature 2025 Survival probability =~ PPP2R1A WT === PPP2R1A mut “1 Median 9.2 versus 66.9 months “* P=0.031 Time after stud
Slide 33: Rationale
Rationale * Ovarian Clear Cell Cancer (OCCC) with acquired mutations reducing PP2A activity are more sensitive to immunotherapy If LB-100 pharmacologic inhibition of PP2A mimics the effect of mutational reduction in PP2A, LB-100 is expected to enhance immunotherapy in OCCC tumors that do not have mu
Slide 34: LB-100 + Immunotherapy: Metastatic MSI Low Colon Cancer
LB-100 + Immunotherapy Metastatic MSI Low Colon Cancer NCT06012734
Slide 35: Rationale
Rationale LB-100 stimulates T-Cell Proliferation LB-100 influences RNA splicing through unbiased phosphoproteomics Generates new antigens for immune stimulation Generates an MSI phenotype in MSS tumors Validated LB-100 + PD-1 in synergy in multiple pre-clinical models The phosphatase inhibitor LB-10
Slide 36: LB-100 + Chemotherapy: Advanced Soft Tissue Sarcoma
LB-100 + Chemotherapy Advanced Soft Tissue Sarcoma NCT05809830
Slide 37: Study design
. Ls se) Study design sce toile: sage 0 sco Phase 1 Trial in Advanced Soft Tissue Sarcoma (ASTS) - ASTS is also a highly (NCT05809830) aggressive cancer with limited effective treatment o Astinsis chug, coxcrulsiicin, Phase 1: To define the safety of combining LB-100 with has been the standard Rx fo
Slide 38: Expanding Horizons in Oncology
Expanding Horizons in Oncology Key Preclinical Studies of LB-100 Investigators Tumor Type Dias (2024) Yen (2021) Maggio et al (2020) Song (2021) Colorectal cancer, pancreatic cancer Colorectal, TNBC, Pancreatic Cancer Glioblastoma Esophageal squamous cell carcinoma Treatment + WEE1 or CHK1 + PD-1 +
Slide 39: Supported by world-class experts & partners
Supported by world-class experts & partners Collaborating with esteemed key opinion leaders and top-tier organizations amplifies our strengths Scientific Advisory Committee Prof. René Bernards =e + Leader in the field of molecular carcinogenesis + Extensive experience in cancer drug development + In
Slide 40: About LIXTE
About LIXTE Clinical-stage pharmaceutical company developing Website Our innovative Our proprietary approach compound LB-100 acts asa potentially providing new options for cancer patients, Big Impact y: Strong Mechanism f Of Action f Conducting , including Advanced Soft Tissue Sarcoma Ovarian Clear
Slide 41: JOIN US
JOIN US in our mission to bring the first PP2A inhibitor to cancer patients. Get in Touch info@lixte.com OLIXTE www.lixte.com LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180, Pasadena, CA 91101
Slide 42: Liora Technologies: Revolutionizing Proton Therapy with the LiGHT Platform
LIORA TECHNOLOGIES REVOLUTIONIZING PROTON THERAPY WITH THE LiGHT PLATFORM Compact, precise, and accessible proton therapy through innovative LINAC technology
Slide 43: Executive Summary
7 UORA Z TECHNOLOGIES EXECUTIVE SUMMARY Liora Technologies has developed LIGHT — a first-of-its-kind electronically controlled proton therapy platform that makes advanced cancer treatment safer, more impactful sessions, and dramatically more cost-effective. $300M 230 MeV Debt-Free $500B+ Proton Beam
Slide 44: Vision & Mission
@ LIGHT mien ine {Tnae or image Guided Hadron Therapy “ecu” Radio Frequency Quadropole RFQ” VISION & oe MISSION ‘Side Coupled Tube Linac pele Acceleration: Achieved maximum energy 230MeV in 2022 40 kev ax L37.5 MeV 15x CCL Vision S Mission Deliver safer, faster, and more effective proton therapy by
Slide 45: The Platform — Breakthrough Technology
7 HORA ECHNOLOGIES The Platform — Breakthrough Technology LIGHT platform * modular, compact LINAC system that electronically adjusts proton beam energy in real time. Validated at 230 MeV at Daresbury * 20 tons vs 90-200 tons legacy gantry systems. * As low as 30% of competitor system costs (# $85 M
Slide 46: How the LiGHT System Works
_— UORA = TECHNOLOGIES How the LiGHT System Works o 16k 26 Modular Compact LINAC Side-Coupled Drift-Tube Linac (SCDTL) + Coupled Cavity Linac (CCL) architecture for Integrated Systems ECR lon Source + RFQ accelerator + Patient Positioning System in 4- unprecedented compactness. room configuration. E
Slide 47: Clinical Advantages
Clinical Advantages Hypofractionation Same therapeutic dose in fewer sessions shorter courses and higher throughput. Adaptive Energy Control Delivers protons precisely at tumor depth without affecting surrounding cells. fed at Daresbury — uORA FLASH potential Ultra-high dose rates to spare healthy t
Slide 48: Cost & Operational Advantage
Cost & Operational Advantage System Cost = $85 M for 4 rooms $200-300 M for 3-4 rooms Weight < 20 tons 90-200 tons Construction Time 12-18 months 3-5 years Proton Loss <5% 90-95 % FLASH Ready Yes (via software) No (physics limit) e Hypofractionation > e@ Reduced radiation to e@ FLASH potential + @ “
Slide 49: Global Oncology Market
— uORA = TECHNOLOGIES Global Oncology Market >$500 B. Radiotherapy room shortfall e ~9,500 rooms worldwide. Average reimbursement per patient $90 K-$100 K (US). re) Light's Cost Advantage Install 4 rooms for # 30 % of competitor cost. Market © Target Segments Hospitals, Cancer Centers, And Opportuni
Slide 50: Business Model — JV Structure with Recurring Revenues
Business Model — JV Structure with Recurring Revenues 3) JV Approach + Liora provides: funding/financing for equipment, site construction, and working capital. « Partners provide: land, clinical services, and patient access. Indicative Site Economics © 3 fractions/hr = 12 hrs/day « 300 days « $3,000
Slide 51: Economic Illustration (4-Room Site)
Economic Illustration (4-Room Site) Total CapEx Annual Revenue Per Site Operating Margin (Target) = $85 M = $129.6 M... 45-55 % @) i Fractions / yr Maintenance Revenue System Lifetime 43,200 Cate Ais 20 + years
Slide 52: Competitive Landscape
Competitive Landscape jon LIGHT + = $85 M for 4 rooms (= 30% of competitors). « Compact system with lighter shielding and treatment chair. « Install in 12-18 months. « Electronically controlled beam energy in real time. * FLASH once enabled, facilitated/implemented with no hardware change required.
Slide 53: Investment Highlights
_— UORA = TECHNOLOGIES Investment Highlights $500B+ Addressing $500 B+ oncology market with 9,500-room shortfall. $129.6M/yr Near-term er 4-room site Hypofractionation, long- Trdnsformational JV model term FLASH — both via = software upgrade, no Share of the ~$129.6 M hardware change. yearly revenue
Slide 54: Adoption Analogy — Proton Therapy's MRI Moment
Adoption Analogy — Proton Therapy’s MRI Moment LiGHT is to Cancer Therapy what Affordable MRI was to Diagnostic Imaging MRI Units + Bulky + $5-10M per stems * Required custom + Smaller + $1-2M mnachine + Faster install financing introduced [1 maiunits 1995 Year < 500 units 10.000 units 25.000+ units
Slide 55: Sustainability & Impact
SUSTAINABILITY & IMPACT Reduces radiation exposure to healthy tissue » improved quality of life. Shorter treatment courses > less patient travel and energy consumption. Modular construction » lower material footprint. Software-based upgrades + extended equipment lifecycle.
Slide 56: Summary & Investment Opportunity
_— UORA = TECHNOLOGIES Summary & Investment Opportunity Transformational Technology + Recurring Economics + Global Need Electronically controlled LINAC — unique in proton therapy. Validated 230 MeV energy delivery. = 30 % of competitor cost, 4x room capacity. $129.6M/yr Per Site (Share of JV) + $4.8
Slide 57: Daresbury Site & Contacts
Daresbury Site & Contacts Daresbury Integration Site ‘STFC Daresbury laboratory, Daresbury, Warrington + . Liora Technologies STFC Daresbury Laboratory, Keckwick Ln, Daresbury, Warrington, WA4 4AD, United Kingdom Email IR@LioraTechnologies.com Website > End-to-end testing: Accelerator & Medical tech
Slide 58: Nomad Power Systems Inc. Corporate
Corporate Nomad Power Systems Inc. Nasdaq : NMAD Corporate Headquarters : Website: Investor Relations: 433 Plaza Real https://ir.nomadpower.com/ ir.info@nomadpower.com Suite 275 Boca Raton, FL 33432 : © 2026 NOMAD Transportable Power Systems, Inc. - Confidential
Nomad Power Systems — Investor Presentation (July 2026) on 6ix